LUMISIGHT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lumisight, and when can generic versions of Lumisight launch?
Lumisight is a drug marketed by Lumicell and is included in one NDA. There are five patents protecting this drug.
This drug has twenty-three patent family members in seven countries.
The generic ingredient in LUMISIGHT is pegulicianine acetate. One supplier is listed for this compound. Additional details are available on the pegulicianine acetate profile page.
DrugPatentWatch® Generic Entry Outlook for Lumisight
Lumisight will be eligible for patent challenges on April 17, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 17, 2029. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LUMISIGHT?
- What are the global sales for LUMISIGHT?
- What is Average Wholesale Price for LUMISIGHT?
Summary for LUMISIGHT
| International Patents: | 23 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| What excipients (inactive ingredients) are in LUMISIGHT? | LUMISIGHT excipients list |
| DailyMed Link: | LUMISIGHT at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for LUMISIGHT
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for LUMISIGHT
LUMISIGHT is protected by five US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of LUMISIGHT is ⤷ Sign Up.
This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting LUMISIGHT
Methods and system for image guided cell ablation with microscopic resolution
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD COMPRISING ADMINISTERING PEGULICIANINE TO A HUMAN AND OBTAINING AN IMAGE OF A TUMOR BED AFTER TUMOR RESECTION TO DISTINGUISH IN SITU CANCER CELLS FROM HEALTHY CELLS
Methods and system for image guided cell ablation with microscopic resolution
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD COMPRISING ADMINISTERING PEGULICIANINE TO A HUMAN AND OBTAINING AN IMAGE OF A TUMOR BED AFTER TUMOR RESECTION TO DISTINGUISH IN SITU CANCER CELLS FROM HEALTHY CELLS
Methods and systems for spatially identifying abnormal cells
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD COMPRISING ADMINISTERING PEGULICIANINE TO A HUMAN AND OBTAINING AN IMAGE OF A TUMOR BED AFTER TUMOR RESECTION TO DISTINGUISH IN SITU CANCER CELLS FROM HEALTHY CELLS
Methods and system for image guided cell ablation with microscopic resolution
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD COMPRISING ADMINISTERING PEGULICIANINE TO A HUMAN AND OBTAINING AN IMAGE OF A TUMOR BED AFTER TUMOR RESECTION TO DISTINGUISH IN SITU CANCER CELLS FROM HEALTHY CELLS
Imaging agent for detection of diseased cells
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD COMPRISING ADMINISTERING PEGULICIANINE TO A HUMAN AND OBTAINING AN IMAGE OF A TUMOR BED AFTER TUMOR RESECTION TO DISTINGUISH IN SITU CANCER CELLS FROM HEALTHY CELLS
FDA Regulatory Exclusivity protecting LUMISIGHT
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lumicell | LUMISIGHT | pegulicianine acetate | POWDER;INTRAVENOUS | 214511-001 | Apr 17, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lumicell | LUMISIGHT | pegulicianine acetate | POWDER;INTRAVENOUS | 214511-001 | Apr 17, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lumicell | LUMISIGHT | pegulicianine acetate | POWDER;INTRAVENOUS | 214511-001 | Apr 17, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Lumicell | LUMISIGHT | pegulicianine acetate | POWDER;INTRAVENOUS | 214511-001 | Apr 17, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lumicell | LUMISIGHT | pegulicianine acetate | POWDER;INTRAVENOUS | 214511-001 | Apr 17, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lumicell | LUMISIGHT | pegulicianine acetate | POWDER;INTRAVENOUS | 214511-001 | Apr 17, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for LUMISIGHT
When does loss-of-exclusivity occur for LUMISIGHT?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 11336660
Patent: Methods and systems for spatially identifying abnormal cells
Estimated Expiration: ⤷ Sign Up
Patent: 16277654
Patent: METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 24724
Patent: PROCEDES ET SYSTEMES DESTINES A IDENTIFIER SPATIALEMENT DES CELLULES ANORMALES (METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS)
Estimated Expiration: ⤷ Sign Up
Patent: 80998
Patent: PROCEDES ET SYSTEMES DESTINES A IDENTIFIER SPATIALEMENT DES CELLULES ANORMALES (METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS)
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 35096
Patent: PROCÉDÉS ET SYSTÈMES DESTINÉS À IDENTIFIER DE MANIÈRE SPATIALE DES CELLULES ANORMALES (METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS)
Estimated Expiration: ⤷ Sign Up
Patent: 46057
Patent: PROCÉDÉS ET SYSTÈMES DESTINÉS À IDENTIFIER SPATIALEMENT DES CELLULES ANORMALES (METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS)
Estimated Expiration: ⤷ Sign Up
Patent: 95853
Patent: SONDES D'IMAGERIE MOLÉCULAIRE ET LEURS COMPOSITIONS (MOLECULAR IMAGING PROBES AND THEIR COMPOSITIONS)
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering LUMISIGHT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 7273873 | ⤷ Sign Up | |
| South Korea | 20160037834 | 의료 이미징 장치 및 사용 방법 (MEDICAL IMAGING DEVICE AND METHODS OF USE) | ⤷ Sign Up |
| Australia | 2011336660 | Methods and systems for spatially identifying abnormal cells | ⤷ Sign Up |
| Canada | 2824724 | PROCEDES ET SYSTEMES DESTINES A IDENTIFIER SPATIALEMENT DES CELLULES ANORMALES (METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS) | ⤷ Sign Up |
| Canada | 2906056 | DISPOSITIF D'IMAGERIE MEDICALE ET SES PROCEDES D'UTILISATION (MEDICAL IMAGING DEVICE AND METHODS OF USE) | ⤷ Sign Up |
| Japan | 6478971 | ⤷ Sign Up | |
| World Intellectual Property Organization (WIPO) | 2014152389 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
